Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 7, 1996, Pages 1623-1627

  Klinker, Hartwig ^a   Langmann, Peter ^a   Richter, Ernst ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; FANSIDAR; FOLINIC ACID; PHENOBARBITAL; PHENYTOIN; PYRIMETHAMINE; RIFAMPICIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; GAS CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER TOXICITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STEADY STATE; TOXOPLASMOSIS;

EID: 0029969972     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.7.1623     Document Type: Article

References (42)

1. Araujo, F. G., D. R. Guptill, and J. S. Remington. 1988. Azithromycin, a macrolide antibiotic with potent activity against Taxoplasma gondii. Antimicrob. Agents Chemother. 32:755-757.
2. Araujo, F. G., J. Huskinson-Mark, W. E. Gutteridge, and J. S. Remington. 1992. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Taxoplasma gondii. Antimicrob. Agents Chemother. 36:326-330.
3. Araujo, F. G., and J. S. Remington. 1974. Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrob. Agents Chemother. 5:647-651.
4. Bachmeyer, C, I. Gorin, J. Deleuze, J. P. Morini, and J. P. Excande. 1994. Pyrimethamine as primary prophylaxis of toxoplasmic encephalitis in patients infected with human immunodeficiency virus: open study. Clin. Infect. Dis. 18:479-480.
5. Bonini, M., F. Mokofio, and S. Barazi. 1981. Contribution au dosage de quatre antipaludéens, chloroquine, quinine, pyriméthamine et sulfadoxine, seuls et en mélange dans les milieux biologiques. J. Chromatogr. 224:332-337.
6. Cavalitto, J. C., C. A. Nichol, W. D. Brenckman, R. L. DeAngelis, D. R. Stickney, W. S. Simmons, and C. W. Sigel. 1978. Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man. Drug Metab. Dispos. 6:329-337.
7. Child, C. G., and J. G. Turcotte. 1964. Surgery and portal hypertension, p. 50. In C. G. Child (ed.), The liver and portal hypertension. The W. B. Saunders Co., Philadelphia.
8. Clumeck, N., J. Sonnet, H. Taelman, F. Mascart-Lemone, M. DeBruyere, P. Vandeperre, J. Dasnoy, L, Marcelis, M. Lamy, C. Jonas, L. Eyckmans, H. Noel, M. Vanhaeverbeek, and J. P. Butzler. 1984. Acquired immunodeficiency syndrome in African patients. N. Engl. J. Med. 310:492-497.
9. Dannemann, B., J. A. McCutchan, D. Israelski, D. Antoniski, C. Leport, B. Luft, J. Nussbaum, N. Clumeck, P. Morlat, J. Chiu, J. L. Vildé, M. Orellana, D. Feigal, A. Vertok, P. Heseltine, J. Leedom, J. Remington, and the California Collaborative Group. 1992. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfonamides. Ann. Intern. Med. 114:33-43.
10. deGans, J., P. Portegies, P. Reiss, D. Troost, T. vanGool, and J. M. A. Lange. 1992. Pyrimethamine alone as maintenance therapy for central nervous system toxoplasmosis in 38 patients with AIDS. J. Acquired Immune Defic. Syndr. 5:137-142.
11. Fernandez-Martin, J., C. Leport, P. Morlat, M. P. Meyohas, J. P. Chauvin, and J. L. Vildé. 1991. Pyrimethamine-clarithromycin combination in therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob. Agents Chemother. 35:2049-2052.
12. Gibaldi, M., and D. Perrier. 1975. Multiple dosing. One-compartment model. In J. Swarbrick (ed.), Drugs and the pharmaceutical sciences, vol. 1. Pharmacokinetics. Marcel Dekker, Inc., New York.
13. Grant, I. H., J. W. Gold, M. Rosenblum, D. Niedzwiecki, and D. Armstrong. 1990. Toxoplasma gondii serology in HIV-infectcd patients: the development of central nervous system toxoplasmosis in AIDS. AIDS 4:519-521.
14. Harris, C., M. Salgo, H. B. Tanowitz, and M. Wittner. 1988. In vitro assessment of antimicrobial agents against Toxoplasma gondii. J. Infect. Dis. 157: 14-22.
15. Haverkos, J. W. 1987. Assessment of therapy for toxoplasma encephalitis. Am. J. Med. 82:907-914.
16. Jacobson, M. A., C. L. Besch, C. Child, R. Hafner, J. P. Matts, K. Muth, D. N. Wentworth, J. D. Neaton, D. Abrams, D. Rimland, G. Perez, I. H. Grant, L. D. Saravolatz, L. S. Brown, L. Deyton, and the Terry Beirn Community Programs for Clinical Research on AIDS. 1994. Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. J. Infect. Dis. 169:384-394.
17. Jones, C. R., and S. M. Ovenell. 1979. Determination of plasma concentrations of dapsone, monoacetyl dapsone and pyrimethamine in human subjects dosed with maloprim. J. Chromatogr. 163:179-185.
18. Katlama, C. 1991. Evaluation of the efficacy and safety of clindamycin plus pyrimethamine for induction and maintenance therapy of toxoplasmic encephalitis in AIDS. Eur. J. Clin. Microbiol. Infect. Dis. 10:189-191.
19. Klinker, H., R. Joeres, and E. Richter. 1991. Pyrimethamine-plasma concentrations during prophylaxis of cerebral toxoplasmosis in patients with advanced HIV infection, abstr. M.B.2014, p. 185. In Program and abstract of the VII International Conference on AIDS, Istituto Superiore di Sanitá, Rome.
20. Klinker, H., R. Joeres, and E. Richter. 1992. High dosed pyrimethamine-prophylaxis against cerebral toxoplasmosis in advanced HIV infection - experience with 44 patients over 409 Months, abstr. PoB 3198, p. B 120. In Program and abstracts of the VIII International Conference on AIDS. CONGREX Holland, Amsterdam.
21. LeLiboux, A., H. Duquesne, G. Montay, D. Chassard, E. Pichard, J. J. Thebault, A. Frydman, and J. Gaillot. 1991. Pharmacokinetics of pyrimethamine in healthy young volunteers using a new solid phase extraction/ HPLC method. Eur. J. Drug Metab. Pharmacokinet. 3:284-290.
22. Leport, C., S. Bastuji-Garin, C. Perronne, D. Salmon, C. Marche, F. Briçaire, and J. L. Vildé. 1989. An open study of the pyrimethamine-clindamycin combination in AIDS patients with brain toxoplasmosis. J. Infect. Dis. 160: 557-558.
23. Leport, C., A. Meulemans, D. Robine, G. Dameron, and J. L. Vildé. 1992. Levels of pyrimethamine in scrum and penetration into brain tissue in humans. AIDS 6:1040-1041.
24. Leport, C., F. Raffi, S. Matheron, C. Katlama, B. Regnier, A. G. Saimot, C. Marche, C. Vedrenne, and J. L. Vildé. 1988. Treatment of central nervous system toxoplasmosis with pyrimethamine-sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous treatment. Am. J. Med. 84:94-100.
25. Luft, B. J., R. Hafner, A. H. Korzun, C. Leport, D. Antoniskis, E. M. Bosler, D. D. Bourland III, R. Uttamchandani, J. Fuhrer, J. Jacobson, Ph. Morlat, J. L. Vildé, J. S. Remington, and Members of the ACTG 077p/ANRS 009 Study Team. 1993. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 329:995-1000.
26. Luft, B. J., and J. S. Remington. 1988. AIDS commentary. Toxoplasmic encephalitis. J. Infect. Dis. 157:1-6.
27. Luft, B. J., and J. S. Remington. 1992. Toxoplasmic encephalitis in AIDS. Clin. Infect. Dis. 15:211-222.
28. Maslo, C., S. Matheron, S. Fegueux, P. de Truchis, A. G. Saimot, and J. P. Coulaud. 1991. Assessment of maintenance therapy for brain toxoplasmosis, abstr. W.B.2365, p. 273. In Program and abstracts of the VII International Conference on AIDS. Istituto Superiore di Sanità, Rome.
29. McLeod, R., D. Mack, R. Foss, K. Boyer, S. Withers, S. Levin, J. Hubbell, and the Toxoplasmosis Study Group. 1992. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Antimicrob. Agents Chemother. 36:1040-1048.
30. McLeod, R., and J. S. Remington. 1992. Toxoplasmosis, p. 1328-1343. In S. Gorbach, N. Blacklow, and J. Bartlett (ed.), Infectious diseases in medicine and surgery. The W. B. Saunders Co., Philadelphia.
31. Opravil, M., B. Joos, and R. Lüthy. 1994. Levels of dapsone and pyrimethamine in scrum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Antimicrob. Agents Chemother. 38:1197-1199.
32. Paulic, P., P. Pestre, E. Bonnet, J. Gasquet, C. Prodhomme, and H. Gallais. 1990. Traitement of brain toxoplasmosis by Fansidar, abstr. Th B. 478, p. 241. In Program and abstracts of the VI International Conference on AIDS. University of California, San Francisco.
33. Remington, J. S., and J. L. Vildé. 1991. Clindamycin for toxoplasma encephalitis in AIDS. Lancet 338:1142-1143. (Letter.)
34. Ruf, B., D. Schürmann, F. Bergmann, W. Schüler-Maué, T. Grünewald, H. J. Gottschalk, H. Witt, and H. D. Pohle. 1993. Efficacy of pyrimethamine/ sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients. Eur. J. Clin. Microbiol. Infect. Dis. 12:325-329.
35. Saba, J., P. Mortal, F. Raffi, V. Hazebroucq, V. Joly, C. Leport, and J. L. Vildé. 1993. Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. Eur. J. Clin. Microbiol. Infect. Dis. 12:853-856.
36. Solbreaux, P., J. Sonnet, and F. Zech. 1990. A retrospective study about the use of cotrimoxazole as diagnostic support and treatment of suspected cerebral toxoplasmosis in AIDS. Acta Clin. Belg. 45:85-96.
37. Weidekamm, E., H. Plozza-Nattebrock, H. Forgo, and U. C. Dubach. 1982. Plasma concentrations of pyrimethaminc and sulphadoxine and evaluation of pharmacokinetic data by computerized curve fitting. Bull. W. H. O. 60: 115-122.
38. Weiss, L. M., C. Harris, M. Berger, H. B. Tanowitz, and M. Wittner. 1988. Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute toxoplasma encephalitis in patients with AIDS. J. Infect. Dis. 157:580-583.
39. Weiss, L. M., B. Luft, H. B. Tanowitz, and M. Wittner. 1992. Pyrimethamine concentrations in serum during treatment of acute murine experimental toxoplasmosis. Am. J. Trop. Med. Hyg. 46:288-291.
40. Zamora, L., J. Mallolas, J. M. Gatell, J. M. Miro, A. Guelar, and E. Soriano. 1991. Primary prophylaxis for CNS toxoplasmosis in HIV infected patients, abstr. W.B. 2342, p. 267. In Program and abstracts of the VII International Conference on AIDS. Istituto Superiore di Sanitá, Rome.
41. Zangerle, R., F. Allerberger, P. Pohl, P. Fritsch, and M. P. Dierich. 1991. High risk of developing toxoplasmic encephalitis in AIDS patients seropositive to Toxoplasma gondii. Med. Microbiol. Immunol. 180:59-66.
42. Zilly, W., D. D. Breimer, and E. Richter. 1975. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur. J. Clin. Pharmacol. 9:219-227.